Business Context and Reporting Period
This Form 8-K Current Report was filed by Tokai Pharmaceuticals, Inc. (not Eledon Pharmaceuticals, Inc.) on April 15, 2015, covering events occurring on April 9, 2015. The filing reports the election of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change is the appointment of Cheryl L. Cohen as a Class I director, effective April 9, 2015. Her term expires at the 2015 annual meeting of stockholders. Ms. Cohen brings significant commercial experience, having previously served as Chief Commercial Officer of Medivation, Inc., where she oversaw the launch of Xtandi.
Compensation and Governance Details
- Cash Retainer: Ms. Cohen will receive an annual cash retainer of $35,000 for Board service, payable quarterly in arrears.
- Initial Stock Option: Granted on April 9, 2015, for 25,000 shares at an exercise price of $11.08 per share. Vesting occurs over three years (one-third on the first anniversary, then quarterly).
- Annual Stock Options: Future grants of 12,000 shares will be made annually after the first Board meeting following each annual stockholder meeting. These vest 100% on the first anniversary.
- Change in Control: All options vest in full upon a change in control of the Company.
- Indemnification: Ms. Cohen entered into a standard indemnification agreement, potentially requiring the Company to cover legal expenses, judgments, and fines arising from her service.
Investor Verification Checklist
- Verify the correct company name is Tokai Pharmaceuticals, Inc., as the input metadata referenced Eledon Pharmaceuticals, Inc.
- Confirm the exercise price of $11.08 per share against the market price on April 9, 2015.
- Review the full text of the indemnification agreement (Exhibit 10.13 referenced in the filing) to understand liability caps.
- Monitor the vesting schedule of the 25,000 initial shares and future annual grants.